Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S–23S
Aghajanian GK, Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31:302–312
Alles GA (1959) Some relations between chemical structure and physiological action of mescaline and related compounds. In: Abramson HA (ed) Neuropharmacology. Madison, Madison, NJ, USA
Appel JB, Callahan PM (1989) Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline. Eur J Pharmacol 159:41–46
Appel JB, Freedman DX (1968) Tolerance and cross-tolerance among psychotomimetic drugs. Psychopharmacologia 13:267–274
Appel JB, White FJ, Holohean AM (1982) Analyzing mechanisms of hallucinogenic drug action with drug discrimination procedures. Neurosci Biobehav Rev 6:529–536
Araneda R, Andrade R (1991) 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40:399–412
Arnt J, Hyttel J (1989) Facilitation of 8-OH-DPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol 161:45–51
Ator NA, Griffiths RR (1989) Asymmetrical cross-generalization in drug discrimination with lorazepam and pentobarbital training conditions. Drug Dev Res 16:355–364
Baker LE, Taylor MM (1997) Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Pharmacol Biochem Behav 57:737–748
Baker LE, Broadbent J, Michael EK, Matthews PK, Metosh CA, Saunders RB, West WB, Appel JB (1995) Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol 6:263–275
Balestrieri A, Fontanari D (1959) Acquired and crossed tolerance to mescaline, LSD-25, and BOL-148. Arch Gen Psychiatry 1:279–282
Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP (1998) Altered brain serotonin homeostasis and locomotor sensitivity to MDMA [“Ecstasy”] in serotonin transporter-deficient mice. Mol Pharmacol 53:649–655
Benneyworth MA, Smith RL, Barrett RJ, Sanders-Bush E (2005) Complex discriminative stimulus properties of [+]lysergic acid diethylamide [LSD] in C57Bl/6J mice. Psychopharmacology 179:854–862
Benneyworth MA, Smith RL, Sanders-Bush E (2008) Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist. Neuropsychopharmacology 33:2206–2216
Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE (2000) Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 43:4701–4710
Boess FG, Martin IL (1994) Molecular biology of 5-HT receptors. Neuropharmacology 33:275–317
Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, Artigas F (2007) In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 191:745–758
Brauer LH, Goudie AJ, deWit H (1997) Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology 130:2–13
Browne RG, Ho BT (1975) Role of serotonin in the discriminative stimulus properties of mescaline. Pharmacol Biochem Behav 3:429–435
Bruins Slot LA, Kleven MS, Newman-Tancredi A (2005) Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49:996–1006
Bubar MJ, Cunningham KA (2006) Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6:1971–1985
Bucan M, Abel T (2002) The mouse: genetics meets behavior. Nat Rev Genet 3:114–123
Burris KD, Breeding M, Sanders-Bush E (1991) (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J Pharmacol Exp Ther 258:891–896
Carroll ME (1990) PCP and hallucinogens. Adv Alcohol Subst Abuse 9:167–190
Chait LD, Uhlenhuth EH, Johanson C (1984) An experimental paradigm for studying the discriminative stimulus properties of drugs in humans. Psychopharmacology 82:272–274
Chausmer AL, Elmer GI, Rubinstein M, Low MJ, Grandy DK, Katz JL (2002) Cocaine-induced locomotor activity and cocaine discrimination in dopamine D2 receptor mutant mice. Psychopharmacology 163:54–61
Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (2006) WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology 188:244–251
Cheng HC, Long JP, Barfknecht CF, Nichols DE (1973) Cardiovascular effects of 2,5-dimethoxy-4-methylamphetamine (DOM, STP). J Pharmacol Exp Ther 186:345–354
Colpaert FC, Niemegeers CJ, Janssen PA (1982) A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther 221:206–214
Corne SJ, Pickering RW (1967) A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia 11:65–78
Creese I, Burt DR, Snyder SH (1975) The dopamine receptor differential binding of d-LSD and related agents to agonist and antagonist states. Life Sci 17:1715–1719
Czoty PW, Howell LL (2000) Behavioral effects of AMI-193, a 5-HT2A-and dopamine D2-receptor antagonist, in the squirrel monkey. Pharmacol Biochem Behav 67:257–264
Darmani NA, Martin BR, Pandey U, Glennon RA (1990) Do functional relationships exist between 5-HT1A and 5-HT2 receptors. Pharmacol Biochem Behav 36:901–906
DeKeyne A, Iob L, Hautefaye P, Millan MJ (2002) The selective serotonin 2A receptor antagonist, MDL100,907, elicits a specific interoceptive cue in rats. Neuropsychopharmacology 26:552–556
DeKeyne A, Iob L, Millan MJ (2003) Generalization of clozapine to other antipsychotic agents in a discriminative stimulus elicited by the serotonin 2A antagonist, MDL100,907. Neuropharmacology 44:604–615
Dixon AK (1968) Evidence of catecholamine mediation in the “aberrant” behavior induced by lysergic acid diethylamide (LSD) in the rat. Experientia 24:743–747
Doblin R (2002) A clinical plan for MDMA [Ecstasy] in the treatment of posttraumatic stress disorder [PTSD]: partnering with the FDA. J Psychoactive Drugs 34:185–194
Dykstra LA, Preston KL, Bigelow GE (1997) Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology 130:14–27
Eckler JR, Reissig CJ, Rabin RA, Winter JC (2004) A 5-HT2C receptor-mediated interaction between 2,5-dimethoxy-4-methylamphetamine [DOM] and citalopram in the rat. Pharmacol Biochem Behav 79:25–30
Elliot EE, Sibley DR, Katz JL (2003) Locomotor and discriminative stimulus effects of cocaine in dopamine D5 receptor knockout mice. Psychopharmacology 169:161–168
English JA, Bruce KH, Paul IA (1999) Increased discriminative stimulus potency of PCP in C57BL/6 mice infected with the LP-BM5 retrovirus. Eur J Pharmacol 367:1–5
Fantegrossi WE, Harrington AW, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KR, Woods JH (2005) Hallucinogen-like actions of 2,5-dimethoxy-4-n-propylthiophenethylamine [2C-T-7] in mice and rats. Psychopharmacology 181:496–503
Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH (2006) Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 83:122–129
Fantegrossi WE, Murnane KS, Reissig CJ (2008a) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17–33
Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC (2008b) Hallucinogen-like effects of N,N-dipropyltryptamine [DPT]: possible mediation by 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav 88:358–365
Filip M, Cunningham KA (2003) Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin2C (5-HT2C) receptors in rat prefrontal cortex. J Pharmacol Exp Ther 306:734–743
Filip M, Bubar MJ, Cunningham KA (2006) Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats. Psychopharmacology 183:482–489
Fiorella D, Rabin RA, Winter JC (1995a) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis. Psychopharmacology 121:347–356
Fiorella D, Helsley SE, Lorrain DS, Palumbo PA, Rabin RA, Winter JC (1995b) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs III: the mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion. Psychopharmacology 121:364–372
Gaddum J (1953) Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J Physiol 121:15P
Gaddum JH (1957) Serotonin-LSD interactions. Ann NY Acad Sci 14:643–647
Gaddum JH, Picarelli ZP (1957) Two kinds of tryptamine receptor. Br J Pharmacol 120(Suppl):134–139
Geter-Douglas B, Witkin JM (1999) Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology 146:280–289
Gingrich JA, Hen R (2001) Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology 155:1–10
Glennon RA (1991) Discriminative stimulus properties of hallucinogens and related designer drugs. In: Glennon RA, Jarbe TUC, Frankenheim J (eds) Drug discrimination: applications to drug abuse research. USGPO, Washington, D.C., pp 25–31
Glennon RA (1999) Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav 64:251–256
Glennon RA, Rosecrans JA, Young R, Gaines J (1979) Hallucinogens as discriminative stimuli: generalization of DOM to 5-methoxy-N,N-dimethyltryptamine. Life Sci 24:993–997
Glennon RA, Young R, Rosecrans JA (1983) Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol 91:189–196
Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505–2511
Goodwin AK, Baker LE (2000) A three-choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and (+)-MDMA in rats. Exp Clin Psychopharmacol 8:415–423
Goodwin AK, Pynnonen DM, Baker LE (2003) Serotonergic-dopaminergic mediation of MDMA’s discriminative stimulus effects in a three-choice discrimination. Pharmacol Biochem Behav 74:987–995
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (2005) Psychological effects of [S]-ketamine and DMT: a double-blind cross-over study in healthy volunteers. Pharmacopsychiatry 38:301–311
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Daumann J, Obradovic M, Kovar KA (2006) Inhibition of return in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology 31:431–441
Gozlan H, Thibault S, Laporte AM, Lima L, Hamon M (1995) The selective 5-HT1A antagonist radioligand [3H]WAY 100,635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. Eur J Pharmacol 288:173–186
Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187:268–283
Heffter A (1896) Ueber Cacteenalkaloide. Ber Deut Chem Ges 29:897–898
Heffter A (1897) Uber Pellote. Arch Exptl Pathol Pharmakol 40:418–425
Herremans AH, van der Heyden JA, van Drimmelen M, Olivier B (1999) The 5-HT1A receptor agonist flesinoxan shares discriminative stimulus properties with some 5-HT2 receptor antagonists. Pharmacol Biochem Behav 64:389–395
Hirschhorn ID, Rosecrans JA (1974) A comparison of the effects of morphine and LSD. Pharmacol Biochem Behav 2:361–366
Hirschhorn ID, Winter JC (1971) Mescaline and lysergic acid diethylamide [LSD] as discriminative stimuli. Psychopharmacologia 22:64–71
Hoch PH, Cattell JP, Pennes HH (1952) Effects of mescaline and lysergic acid (d-LSD-25). Am J Psychiatry 108:579–584
Hofmann A (1959) Psychotomimetic drugs, chemical and pharmacological aspects. Acta Physiol Pharmacol Neerl 8:240–258
Hofmann A (1968) Psychotomimetic agents. In: Burger A (ed) Drugs affecting the central nervous system. Edward Arnold, London, pp 169–235
Hollister LE, Richards RK, Gillespie HK (1968) Comparison of tetrahydrocannabinol and synhexyl in man. Clin Pharmacol Ther 9:783–791
Hollister LE, Shelton J, Krieger G (1969a) A controlled comparison of lysergic acid diethylamide [LSD] and dextroamphetamine in alcoholics. Am J Psychiatry 125:1352–1357
Hollister LE, MacNichol MF, Gillespie HK (1969b) An hallucinogenic amphetamine analog (DOM) in man. Psychopharmacologia 14:62–73
Horita A, Nair X, Hamilton AE (1972) L- -methyl- -hydrazino- -(3,4-dihydroxyphenyl)propionic acid: relative lack of antidecarboxylase activity in adrenals. Science 176:931–932
Isbell H, Wolbach AB, Winkler A, Miner EJ (1961) Cross tolerance between LSD and psilocybin. Psychopharmacologia 2:147–159
Isbell H, Gorodetzsky CW, Jasinski D, Claussen U, von Spulak F, Korte F (1967) Effects of (-)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia 1967:184–188
Ismaiel AM, De Los Angeles J, Titeler M, Ingher S, Glennon RA (1993) Antagonism of the 1-[2,5-dimethoxy-4-methylphenyl]-2-aminopropane stimulus with a newly identified 5-HT2 versus 5-HT1C-selective antagonist. J Med Chem 36:2519–2525
Johanson C, Kilbey M, Gatchalian K, Tancer M (2006) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate between d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81:27–36
Jones HE, Li H, Balster RL (1998) Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol Biochem Behav 59:413–418
Kamien J, Bickel W, Hughes J, Higgins S, Smith B (1993) Drug discrimination by humans compared to nonhumans: current status and future directions. Psychopharmacology 111:259–270
Katz JL, Chausmer AL, Elmer GI, Rubenstein M, Low MJ, Grandy DK (2003) Cocaine-induced locomotor activity and cocaine discrimination in dopamine D4 receptor mutant mice. Psychopharmacology 170:108–114
Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968–981
Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004) Pharmacological characterization of the agonist radioligands binding site of 5-HT2A, 5-HT2B, and 5-HT2C receptors. N-S Arch Pharmacol 370:114–123
Koek W (1999) N-Methyl-d-aspartate antagonists and drug discrimination. Pharmacol Biochem Behav 64:275–281
Krall CM, Richards JB, Rabin RA, Winter JC (2007) Marked decrease of LSD-induced stimulus control in serotonin transporter knockout mice. Pharmacol Biochem Behav 88:349–357
Kuhn DM, White FJ, Appel JB (1978) The discriminative stimulus properties of LSD: mechanisms of action. Neuropharmacology 17:257–263
Leysen JE (1985) Serotonin receptor binding sites. In: Green AR (ed) Neuropharmacology of serotonin. Oxford Press, Oxford, pp 86–97
Li JX, Rice KC, France CP (2008) Discriminative stimulus effects of 1-[2,5-dimethoxy-4methylphenyl]-2-aminopropane in rhesus monkeys. J Pharmacol Exp Ther 324:827–833
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959) Study of the new schizophrenomimetic drug l sernyl. Arch Neurol Psychiatry 81:363–368
Marona-Lewicka D, Nichols DE (1995) Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists. Psychopharmacology 120:384–391
Marona-Lewicka D, Nichols DE (2007) Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav 87:453–461
Marona-Lewicka D, Thisted RA, Nichols DE (2005) Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology 180:427–435
Marona-Lewicka D, Chemel BR, Nichols DE (2008) Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen. Psychopharmacology. doi:10.1007/s00213-008-1238-0, Epub ahead of print
Martel JC, Leduc N, Ormiere AM, Faucilion V, Danty N, Culie C, Cussac D, Newman-Tancredti A (2007) WAY-100635 has high selectivity for 5-HT1A versus dopamine D4 receptors. Eur J Pharmacol 574:15–19
Martin WR, Eades CG (1970) The action of tryptamine on the dog spinal cord and its relationship to the agonistic actions of LSD-like psychotogens. Psychopharmacologia 17:242–257
Meltzer HY, Simonovic M, Gudelsky GA (1983) Effects of pirenperone and ketanserin on rat prolactin secretion in vivo and in vitro. Eur J Pharmacol 19:83–89
Middaugh LD, Favara JP, Boggan WO, Stringer AJ (1988) Discriminative properties of phencyclidine in mice: generalization to ketamine and monohydroxy metabolites. Psychopharmacology 96:381–384
Morris K (2008) Research on psychedelics moves into the mainstream. Lancet 371:1491–1492
Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2008) Aripiprazole ameliorates PCP-induced impairment of recognition memory through dopamine D(1) and serotonin 5-HT1A receptors. Psychopharmacology. doi:10.1007/s00213-008-1240-6, Epub ahead of print
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Nichols DE, Nichols CD (2008) Serotonin receptors. Chem Rev 108:1614–1641
Nielsen EB (1985) Discriminative stimulus properties of lysergic acid diethylamide in the monkey. J Pharmacol Exp Ther 234:244–249
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Marazova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102–1107
Pauwels PJ, Van Gompel P, Leysen JE (1993) Activity of serotonin receptor agonists, partial agonists, and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells. Biochem Pharmacol 45:375–383
Pazos A, Hoyer D, Palacios JM (1984) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 106(3):539–546, Nov 27
Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]-5-hydroxytryptamine, [3H]lysergic acid diethylamide, and [3H]spiroperidol. Molecular Pharmacol 16:687–699
Rabin RA, Doat M, Winter JC (2000) Role of serotonergic 5-HT2A receptors in the psychotomimetic actions of phencyclidine. Int J Neuropsychopharmacol 3:333–338
Rabin RA, Regina MJ, Doat MM, Winter JC (2002) 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav 72:29–37
Rapport M (1949) Serum vasoconstrictor (serotonin) the presence of creatinine in the complex; a proposed structure of the vasoconstrictor principle. J Biol Chem 180:961–969
Reissig CJ, Eckler JR, Rabin RA, Winter JC (2005) The 5-HT1A receptor and the stimulus effects of LSD in the rat. Psychopharmacology 182:197–204
Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68:29–39
Rosecrans JA, Glennon RA (1979) Drug-induced cues in studying mechanisms of drug action. Neuropharmacology 18:981–989
Sai-Halisz A, Brunecker G, Szara S (1958) Dimethyltryptamine: a new psycho-active drug. Psychiatr Neurol 35:285–301
Sanders-Bush E, Burris KD, Knoth K (1988) Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 246:924–928
Schechter MD, Rosecrans JA (1972) LSD as a discriminative cue: drugs with similar stimulus properties. Psychopharmacologia 26:313–316
Schneider CW, Chenoweth MB (1970) Effects of hallucinogenic and other drugs on the nest-building behavior of mice. Nature 225:1262–1263
Schreiber R, Brocco M, Millan MJ (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the ‘atypical’ antipsychotics, clozapine and risperidone. Eur J Pharmacol 264:99–102
Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101–112
Schultes RE, Hofmann A (1980) The botany and chemistry of hallucinogens. Charles C. Thomas, Springfield
Seong E, Seasholtz AF, Burmeister M (2002) Mouse models of psychiatric disorders. Trends Genet 18:643–650
Shannon EE, Shelton KL, Vivian JA, Yount I, Morgan AR, Homanics GE, Grant KA (2004) Discriminative stimulus effects of ethanol in mice lacking the gamma-aminobutyric acid type A receptor delta subunit. Alcoholism Clin Expt Res 28:906–913
Shulgin A, Shulgin A (1991) PiHKAL, a chemical love story. Transform Press, Berkeley
Shulgin A, Shulgin A (1997) TiHKAL, the continuation. Transform Press, Berkeley
Silva MT, Calil HM (1975) Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia 42:63–71
Silverman PB, Ho BT (1980) The discriminative stimulus properties of 2,5-dimethoxy-4-methylamphetamine (DOM): differentiation from amphetamine. Psychopharmacology 68:209–215
Smith RL, Barrett RJ, Sanders-Bush E (2003) Discriminative stimulus properties of 1-2(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+)DOI] in C57BL/6J mice. Psychopharmacology 166:61–68
Smythies JR, Sykes EA (1964) The effect of mescaline upon the conditioned avoidance response in the rat. Psychopharmacologia 6:163–172
Snigdha S, Neill JC (2008) Improvement of phencyclidine-induced social behavior deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 191:26–31
Snoddy AM, Tessel RE (1983) Nisoxetine and amphetamine share discriminative stimulus properties in mice. Pharmacol Biochem Behav 19:205–210
Snyder SH, Faillace L, Hollister L (1968) 2,5-Dimethoxy-4-methylamphetamine: new hallucinogenic drug. Science 159:1492
Spath E (1919) Uber die Anhalonium-Alkaloide, I. Anhalin und Mezcalin. Monograph. Fur Chem 40:129–152
Spencer DG Jr, Glaser T, Traber J (1987) Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine. Psychopharmacology 93:158–166
Stolerman IP, Kamien JB (2004) Drug discrimination bibliographic database. www.dd-database.org
Stolerman IP, Chamberlain S, Bizarro L, Fernandes C, Schalkwyk L (2004) The role of nicotinic alpha7 subunits in nicotine discrimination. Neuropharmacology 46:363–371
Strassman RJ (1991) Human hallucinogenic drug research in the United States: a present-day case history and review of the process. J Psychoactive Drugs 23:29–38
Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner RK (1994) Dose response study of N,N-dimethyltryptamine in humans. Arch Gen Psychiatr 51:98–108
Szara S (1956) Dimethyltryptamine: its metabolism in man; the relation of its psychotic effect to serotonin metabolism. Experientia 12:441–442
Szara S (1957) The comparison of the psychotic effects of tryptamine derivatives with the effects of mescaline and LSD-25 in self-experiments. In: Garattini S, Ghetti V (eds) Psychotropic drugs. Elsevier, Amsterdam
Torres M, Repke D (2006) Anadenanthera: visionary plant of ancient South America. The Haworth Herbal Press, New York, pp 143–186
Uyeno ET (1969) Alteration of a learned response of the squirrel monkey by hallucinogens. Int J Neuropharmacol 8:245–253
Uyeno ET, Mitoma C (1969) The relative effectiveness of several hallucinogens in disrupting maze performance by rats. Psychopharmacologia 16:73–80
Vollenweider FX, Gamma A, Bar T, Babler A, Vogel H, Hell D (1996) Ketanserin, a 5-HT2 antagonist, but not haloperidol, effectively blocks psilocybin-induced model psychosis in healthy volunteers. WPA Abstract book, 116
Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogen H, Hell D (1998a) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroRep 9:3897–3902
Vollenweider FX, Gamma A, Liechti M, Huber T (1998b) Psychological and cardiovascular effects and short-term sequelae of MDMA [“Ecstasy”] in MDMA-naïve healthy volunteers. Neuropsychopharmacol 19:241–251
Vollenweider FX, Vontobel P, Hell D, Leenders KL (1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with [11C]raclopride. Neuropharmacol 20:424–433
Webster (1993) Webster’s third new international dictionary of the English language unabridged. Merriam Webster, Springfield
Weinberg AM (1972) Science and trans-science. Science 177:211–221
White FJ, Simmons MA, West KB, Holohean AM, Appel JB (1980) The effect of serotonin depletion on the discriminability of LSD. Pharmacol Biochem Behav 13:569–574
Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282:699–706
Winter JC (1971) Tolerance to a behavioral effect of lysergic acid diethylamide and cross-tolerance to mescaline in the rat: absence of a metabolic component. J Pharmacol Exp Ther 178:625–630
Winter JC (1974) Hallucinogens as discriminative stimuli. Fed Proc 33:1825–1832
Winter JC (1975) Blockade of the stimulus properties of mescaline by a serotonin antagonist. Arch Int Pharmacodyn Ther 214:250–253
Winter JC (1978) Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine. J Pharmacol Exp Ther 204:416–423
Winter CA, Flataker L (1956) Effects of LSD upon performance of trained rats. PSEBM 92:285–289
Winter JC, Gessner PK (1968) Phenoxybenzamine antagonism of tryptamines, their indene isosteres, and 5-hydroxytryptamine in the rat stomach fundus preparation. J Pharmacol Exp Ther 162:286–293
Winter JC, Fiorella DJ, Timineri DM, Filipink RA, Helsley SE, Rabin RA (1999) Serotonergic receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav 64:283–293
Winter JC, Doat M, Rabin RA (2000a) Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists. A link between the glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci 68:337–344
Winter JC, Filipink RF, Timineri D, Helsley SE, Rabin RA (2000b) The paradox of 5-methoxy-N,N-dimethyltryptamine: a hallucinogen which induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav 65:75–82
Winter JC, Eckler JR, Rabin RA (2004) Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology 172:233–240
Winter JC, Kiers AK, Zimmerman MD, Reissig CJ, Eckler JR, Ullrich T, Rice KC, Rabin RA, Richards JB (2005a) The stimulus properties of LSD in C57BL/J mice. Pharmacol Biochem Behav 81:830–837
Winter JC, Eckler JR, Rice KC, Rabin RA (2005b) Serotonergic–glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram. Pharmacol Biochem Behav 81:694–700
Winter JC, Rice KC, Amorosi DJ, Rabin RA (2007) Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav 87:472–480
Wolbach AB, Isbell H, Miner EJ (1962a) Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions. Psychopharmacologia 12:1–14
Wolbach AB, Isbell H, Miner EJ (1962b) Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia. 3:219–223
Wooley DW, Shaw E (1954) A biochemical and pharmacological suggestion about certain mental disorders. PNAS [USA] 40:228–235
Young R, Rosecrans JA, Glennon RA (1982) Comparative discriminative stimulus effects of 5-methoxy-N,N-dimethyltryptamine and LSD. Life Sci 30:2057–2062
Young R, Rosecrans JA, Glennon RA (1983) Behavioral effects of 5-methoxy-N,N-dimethyltryptamine and dose-dependent antagonism by BC-105. Psychopharmacology 80:156–160
Young R, Rosecrans JA, Glennon RA (1986) Further studies on the dose-dependent stimulus properties of 5-methoxy-N,N-dimethyltryptamine. Pharmacol Biochem Behav 25:1207–1210
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4